Bridion Injection, Solution
Product Images NDC 71872-7187

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Bridion (NDC 71872-7187). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medical Purchasing Solutions, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

71872-7187-1.pdp (71872 7187 1)

71872-7187-1.pdp (71872 7187 1)
This is a description of a medication called Bridion® (Sugammadex) Injection for intravenous use only. The medication is manufactured in the Netherlands and is supplied in a single-dose vial of 2 ml, containing 200 mg/2 ml (100 mg/mL) Sugammadex. It is a sterile non-pyrogenic aqueous solution and can be stored at 25°C (77°F) with excursions permitted to 15-30°C (59-86°F). It should be used within five days if not protected from light. The osmolality of the product is between 300 and 500 mOsmol/kg. The usual dosage is specified in the enclosed package insert. This medication is repackaged and distributed by Medical Purchasing Solutions, Scottsdale, AZ 85260.*
FDA Label Image

Chemical Structure (Bridion 01)

Chemical Structure (Bridion 01)
FDA Label Image

Chemical Structure (Bridion 02)

Chemical Structure (Bridion 02)
FDA Label Image

Figure 1 (Bridion 03)

Figure 1 (Bridion 03)
The text describes a graph showing the median cumulative recovery times for two different drugs, sugammadex and neostigmine. The recovery times are measured in minutes and the graph also includes quartiles for sugammadex. There is a time to recovery in minutes on the X-axis and cumulative recovery rate on the Y-axis. The graph also shows product-limit estimates and mentions censored observations.*
FDA Label Image

Figure 2 (Bridion 04)

Figure 2 (Bridion 04)
This text provides information on the cumulative recovery rate for sugammadex and neostigmine as represented by their median and quartile recovery times in minutes. It also includes a graph depicting the time to recovery for the drugs. The study was conducted with vecuronium patients where 48 were treated with sugammadex and 45 were treated with neostigmine. The recovery times were estimated using product-limit estimates and include censored observations.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.